【摘要】 目的:探究青少年精神分裂症患者应用奥氮平、阿立哌唑治疗后对其代谢综合征的影响。方法:选取本院2020年1月—2021年1月收治入院的青少年精神分裂症患者60例,利用随机数字表法分为A、B两组,每组30例,分别使用奥氮平、阿立哌唑治疗。比较两组阴性与阳性症状量表(PANSS)评分、体质指数(BMI)、糖脂代谢指标[三酰甘油(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)、空腹血糖(FBG)]、血清泌乳素(PRL)、甲状腺功能三项[总三碘甲腺原氨酸(TT3)、总甲状腺素(TT4)、促甲状腺激素(TSH)]指标以及用药后代谢综合征发生率。结果:两组治疗后PANSS评分较治疗前下降,差异有统计学意义(P<0.05),但组间比较,差异无统计学意义(P>0.05);A组治疗后BMI指数、FBG、TG、LDL-C、TT3、TSH、PRL较治疗前上升,且高于B组;HDL-C、TT4水平较治疗前降低,且低于B组,差异有统计学意义(P<0.05);B组治疗前后各指数比较,差异无统计学意义(P>0.05)。两组代谢综合征发生率比较,差异无统计学意义(P>0.05)。结论:奥氮平与阿立哌唑对青少年精神分裂症的治疗均具有较好疗效,但奥氮平对糖脂代谢以及体重具有明显影响,可能增加代谢综合征发生的风险。更多还原

【Abstract】 Objective: To explore the influence of olanzapine and aripiprazole on the incidence rate of metabolic syndrome in adolescents with schizophrenia. Methods: A total of 60 adolescent patients with schizophrenia treated in the hospital were selected between January 2020 and January 2021, and were divided into two group A and group B by using the random number table method, with 30 cases in each group, olanzapine and aripiprazole were used respectively. The scores of Positive and Negative Syndrome Scale（PANSS）, body mass index（BMI）, glucolipid metabolism indicators [triacylglycerol（TG）, high-density lipoprotein cholesterol（HDL-C）, low-density lipoprotein cholesterol（LDL-C）, fasting blood glucose（FBG）], serum prolactin（PRL）, three items of thyroid function [total triiodothyronine（TT3）, total thyroxine（TT4）, thyroidstimulating hormone（TSH）] and incidence rate of metabolic syndrome after medication were combined between the two groups. Results: The PANSS scores of the two groups after treatment were lower than those before treatment（P <0.05）, and there were no statistically significant differences between the groups（P>0.05）. After treatment, BMI index, FBG, TG, LDL-C, TT3, TSH and PRL were increased in the group A compared to before treatment, and were higher than those in the group B. The levels of HDL-C and TT4 were decreased, and were lower than those in the group B（P<0.05）. There were no significant differences in the indicators in the group B before and after treatment（P>0.05）. The incidence rate of metabolic syndrome of 16.67% in the group A was higher than 0% in the group B,But there is no statistical difference（P>0.05）. Conclusion: Both olanzapine and aripiprazole have good efficacy in the treatment of adolescent schizophrenia. Olanzapine has a significant effect on glucolipid metabolism and body weight, and it may increase the risk of metabolic syndrome while aripiprazole has little effect on it.更多还原